Hosted by STORM Therapeutics in Cambridge UK

First RNA Epigenetics Conference Hosted by STORM Therapeutics in Cambridge UK

CAMBRIDGE, England: STORM Therapeutics, a drug discovery firm focused on discovering tiny molecular therapies that modulate RNA epigenetics, announced today that it will host a global meeting focusing on the developing sector of RNA epigenetics.
RNA (ribonucleic acid) is the only immediate human genome product and one form of RNA, mRNA, functions as a basis for the synthesis of all proteins, cell molecular machines. RNA is also considered to be a main player in cellular decision making, especially as non-coding RNA (ncRNA) such as microRNA, piRNA, and long non-coding RNA.
The conference, entitled RNA epigenetics in human disease, is the first of its kind to be held at St Catharine’s College, Cambridge, UK on 17-20 September 2019. RNA epigenetics is an interesting, emerging, innovative biology region and also STORM is the first firm to explore the field’s therapeutic potential.
STORM was formed in 2015 and is a spin-out university in Cambridge that translates the groundbreaking work of Professors Tony Kouzarides and Eric Miska in RNA epigenetics into the discovery of first-class oncology drugs and other diseases. STORM addresses disease by modulating enzyme-modifying RNA and develops a distinctive platform to tackle these classes of enzymes, including methyltransferases of RNA.
The conference will host an amazing line-up of RNA epigenetics global speakers and professionals. The list of speakers includes:
Richard Gregory – Principal Investigator – Boston Children’s Hospital
Samie Jaffrey – Professor – Weill Medical College, Cornell University
Robert Copeland – President, Chief Scientific Officer & Co-founder – Accent Therapeutics
Gerhard Muller – Chief Scientific Officer – Gotham Therapeutics
Chuan He – Professor – The University of Chicago
Eric Miska – Gurdon Institute and STORM Therapeutics
Tony Kouzarides – Gurdon Institute and STORM Therapeutics
Oliver Rausch – Chief Scientific Officer – STORM Therapeutics